This is a HIA partner technology
Wet macular degeneration is the advanced stage of age-related macular degeneration (AMD) and affects approximately 10-15% of patients with AMD, yet accounts for more than 80% of all vision loss associated with the disease. Wet AMD is caused by abnormal blood vessel growth in the retina, known as choroidal neovascularization.
Mitotic kinesins are motor proteins required to facilitate proper cell division (mitosis). Recent studies by Dr. Rosenfeld and his team have shown that one of these kinesins, Eg5, is up-regulated in tumor cells from human glioblastomas.
Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. Dr. Rich and his team have developed aptamers consisting of a single stranded nucleic acids having 100 nucleotides or less that specifically binds to tumor initiating cancer cells, identified by screening a large pool of randomly generated aptamers to obtain a discrete set of them that specifically bind to tumor initiating cancer cells, such as those found in brain cancer or glioblastoma.
The complement system is emerging as a new target for treating many diseases. For example, Eculizumab, a humanized monoclonal antibody against complement component 5 (C5), has been approved for paroxysmal nocturnal hemoglobinuria (PNH) in which patient erythrocytes are lysed by complement.
Mantle cell lymphoma (MCL) is incurable using current standard therapeutic regimens. Additionally, there are relatively few cell lines and mouse models to support drug discovery and development efforts.
Integration of high-throughput radiation survival profiling with large-scale cancer genomic data suggests AR expression is associated with therapeutic resistance in breast cancer. Our analysis nominates anti-androgen therapies, which are commercially available and currently in clinical use in prostate and breast cancer, as therapeutic sensitizers in select AR positive breast cancer.
The technology is a diagnostic tool that assesses an actionable biomarker for treatment selection in the prostate cancer care continuum.
Dr. Lin's research suggests that targeting CD6 gene is a promising effective treatment for Multiple Sclerosis.
Despite progress, multiple myeloma remains largely incurable, recruiting relapses from genetically heterogeneous multiple myeloma subclones.
Researchers at Cleveland Clinic have developed peptide tracers that target prostate specific membrane antigen (PSMA).